In contrast, in multiple myeloma (MM), oncogenic overexpression of ITGB7 in high-risk cases enhances interactions between malignant plasma B-cells and stromal cells, leading to cell-adhesion-mediated drug resistance (50). This evidence concerns the gene ITGB7 and plasma cell myeloma.